WAU
ABBV icon

Wellington-Altus USA’s AbbVie ABBV Stock Holding History

Wellington-Altus USA’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$73.1K Buy
336
+110
+49% +$23.7K 0.05% 253
2026
Q1 		$56.9K Sell
226
-172
-43% -$38.2K 0.03% 320
2025
Q4 		$90.9K Buy
+398
New +$90.7K 0.07% 214

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Wellington-Altus USA's ABBV Position: Q2 2026 in Review

Wellington-Altus USA increased its AbbVie (ABBV) stake by 49% in Q2 2026, buying an estimated $23.7K and bringing the position to 336 shares worth $73.1K. The position accounts for 0.05% of the portfolio, ranked #253.

Wellington-Altus USA first reported a position in ABBV in Q4 2025 and has held it in 3 quarters since. The position peaked at $90.9K in Q4 2025. 4,227 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Wellington-Altus USA held 336 shares of AbbVie worth $73.1K as of Q2 2026.
  • Wellington-Altus USA bought 110 AbbVie shares in Q2 2026, an estimated $23.7K.
  • AbbVie made up 0.05% of Wellington-Altus USA's portfolio in Q2 2026, its #253 holding.
  • Wellington-Altus USA first reported a position in AbbVie in Q4 2025 and has held it in 3 quarters since.
  • Wellington-Altus USA's AbbVie position peaked at $90.9K in Q4 2025.
  • 4,227 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Wellington-Altus USA's 13F filing for Q2 2026, filed 17 Sep 2026.